Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets (R-DAPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03787927
Recruitment Status : Recruiting
First Posted : December 27, 2018
Last Update Posted : March 25, 2019
Sponsor:
Collaborator:
National Blood Foundation
Information provided by (Responsible Party):
Bloodworks

Brief Summary:
This study aims to determine whether cold-stored platelets (CSP) are equally, more effective, or uniquely effective at reversing the effect of dual antiplatelet therapy in healthy human subjects compared to room-temperature-stored platelets (RTP). The investigators plan to enroll healthy human subjects without risk factors for bleeding to achieve 60 complete data sets. Each subject will donate two apheresis platelet units. One platelet unit will be stored in the cold (CSP) and one platelet unit will be stored at room temperature (RTP). Subjects will be given dual anti-platelet therapy (aspirin and clopidogrel) prior to autologous transfusion of each unit. Platelet function testing will be performed before and after transfusion to measure reversal of the antiplatelet drugs.

Condition or disease Intervention/treatment Phase
Bleeding Platelet Dysfunction Due to Drugs Platelet Dysfunction Drug: Autologous Platelet Transfusion (room-temperature-stored) Drug: Autologous Platelet Transfusion (cold-stored 5 days) Drug: Autologous Platelet Transfusion (cold-stored 10 days) Drug: Autologous Platelet Transfusion (cold-stored 15 days) Drug: Aspirin Drug: Clopidogrel Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets
Actual Study Start Date : December 3, 2018
Estimated Primary Completion Date : December 3, 2021
Estimated Study Completion Date : December 3, 2021

Arm Intervention/treatment
5 day CSP, then 5 day RTP

Participants will first complete collection and transfusion of 5 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.

The first 20 participants who complete the study will be randomized to this arm or '5 day RTP, then 5 day CSP.'

Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)

Drug: Autologous Platelet Transfusion (room-temperature-stored)
The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.

Drug: Autologous Platelet Transfusion (cold-stored 5 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.

Drug: Aspirin
Aspirin (325mg) will be administered the day before every transfusion.

Drug: Clopidogrel
Clopidogrel (600mg) will be administered the day before every transfusion.

5 day RTP, then 5 day CSP

Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 5 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.

The first 20 participants who complete the study will be randomized to this arm or '5 day CSP, then 5 day RTP.'

Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)

Drug: Autologous Platelet Transfusion (room-temperature-stored)
The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.

Drug: Autologous Platelet Transfusion (cold-stored 5 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.

Drug: Aspirin
Aspirin (325mg) will be administered the day before every transfusion.

Drug: Clopidogrel
Clopidogrel (600mg) will be administered the day before every transfusion.

5 day RTP, then 10 day CSP

Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 10 day autologous CSP (cold-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.

After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'

Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)

Drug: Autologous Platelet Transfusion (room-temperature-stored)
The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.

Drug: Autologous Platelet Transfusion (cold-stored 10 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.

Drug: Aspirin
Aspirin (325mg) will be administered the day before every transfusion.

Drug: Clopidogrel
Clopidogrel (600mg) will be administered the day before every transfusion.

5 day RTP, then 15 day CSP

Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 15 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.

After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'

Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)

Drug: Autologous Platelet Transfusion (room-temperature-stored)
The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.

Drug: Autologous Platelet Transfusion (cold-stored 15 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 15 days of storage.

Drug: Aspirin
Aspirin (325mg) will be administered the day before every transfusion.

Drug: Clopidogrel
Clopidogrel (600mg) will be administered the day before every transfusion.

10 day CSP, then 5 day RTP

Participants will first complete collection and transfusion of 10 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.

After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'

Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)

Drug: Autologous Platelet Transfusion (room-temperature-stored)
The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.

Drug: Autologous Platelet Transfusion (cold-stored 10 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.

Drug: Aspirin
Aspirin (325mg) will be administered the day before every transfusion.

Drug: Clopidogrel
Clopidogrel (600mg) will be administered the day before every transfusion.

15 day CSP, then 5 day RTP

Participants will first complete collection and transfusion of 15 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.

After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'

Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)

Drug: Autologous Platelet Transfusion (room-temperature-stored)
The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.

Drug: Autologous Platelet Transfusion (cold-stored 15 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 15 days of storage.

Drug: Aspirin
Aspirin (325mg) will be administered the day before every transfusion.

Drug: Clopidogrel
Clopidogrel (600mg) will be administered the day before every transfusion.




Primary Outcome Measures :
  1. Verify Now (PRU): αIIbβ3 (GPIIb-IIIa) integrin activation changes between DAPT loaded pre-transfusion, 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion, baseline [ Time Frame: Measured at baseline, pre-transfusion (after administration of dual anti-platelet therapy), 1 hour post-transfusion, 24 hour post-transfusion ]
    Measured by Verify Now (PRU)

  2. Verify Now: αIIbβ3 (GPIIb-IIIa) integrin activation changes between DAPT loaded pre-transfusion, 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion, baseline [ Time Frame: Measured at baseline, pre-transfusion (after administration of dual anti-platelet therapy), 1 hour post-transfusion, 24 hour post-transfusion ]
    Measured by Verify Now (ARU)

  3. PAC-1: αIIbβ3 (GPIIb-IIIa) integrin activation changes between DAPT loaded pre-transfusion, 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion, baseline [ Time Frame: Measured at baseline, pre-transfusion (after administration of dual anti-platelet therapy), 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion ]
    Measured by PAC-1 antibody binding by flow cytometry


Secondary Outcome Measures :
  1. LTA: αIIbβ3 (GPIIb-IIIa) integrin activation changes from DAPT loaded pre-transfusion, 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion, baseline [ Time Frame: Measured at baseline, pre-transfusion (after administration of dual anti-platelet therapy), 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion ]
    Light Transmittance Aggregometry

  2. P-Selectin:αIIbβ3 (GPIIb-IIIa) integrin activation changes between DAPT loaded pre-transfusion, 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion, baseline [ Time Frame: Measured at baseline, pre-transfusion (after administration of dual anti-platelet therapy), 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion ]
    Measured by alpha-granule secretion (P-Selectin) by flow cytometry

  3. Beeding time testing (in-vivo) changes between DAPT loaded pre-transfusion, 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion, baseline [ Time Frame: Measured at baseline, pre-transfusion (after administration of dual anti-platelet therapy), 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion ]
    in-vivo subject testing

  4. CBC changes between DAPT loaded pre-transfusion, 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion, baseline [ Time Frame: Measured at baseline, pre-transfusion (after administration of dual anti-platelet therapy), 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion ]
  5. Platelet unit blood gas: changes during storage [ Time Frame: day of collection, day of transfusion ]
    during storage of the units

  6. Platelet unit Annexin V: changes during storage [ Time Frame: day of collection, day of transfusion ]
  7. Thromboxane B2 ELISA changes between DAPT loaded pre-transfusion, 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion, baseline [ Time Frame: Measured at baseline, pre-transfusion (after administration of dual anti-platelet therapy), 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion ]
  8. Vasodilator-stimulated phosphoprotein (VASP) changes [ Time Frame: Measured at baseline, pre-transfusion (after administration of dual anti-platelet therapy), 1 hour post-transfusion, 4 hour post-transfusion, 24 hour post-transfusion ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

The subject is in good health, is taking no excluded medications and meets platelet donor suitability requirements aimed at assuring donor safety.

  1. Subject self-reports that he or she feels well and healthy
  2. Subjects must be 18-59 years old, of either sex
  3. Temperature: less than or equal to 99.5 F
  4. Resting blood pressure: systolic less than or equal to 180 mmHg, diastolic less than or equal to100 mmHg
  5. Resting heart rate: 40 to 100 beats per minute
  6. Weight: greater than or equal to110 pounds,
  7. Hematocrit: greater than or equal to 35 percent for females, greater than or equal to 38 percent for males, but not greater than 55 percent
  8. Platelet count able to achieve target platelet yield per apheresis machine configuration parameters
  9. Subjects must be able to read, understand and sign the informed consent document and commit to the study follow-up schedule. The ability to read and speak English is required for participation.
  10. Subject must agree to avoid taking any aspirin or aspirin-containing drugs (e.g., Alka-Seltzer, Bufferin, Excedrin) or NSAIDs (e.g.,Feldene, Motrin, Aleve, Advil) or other drugs known to affect platelet function throughout their study participation.
  11. Subjects must agree to avoid calcium channel blockers such as amlodipine (Norvasc), felodipine, and verapamil (Verelan, Calan) and proton pump inhibitors (PPIs) such as omeprazole (Prilosec), lansoprazole (Prevacid), esomeprazole (Nexium) and pantoprazole (Protonix) until all study blood draws are concluded. These classes of drugs may interfere with the action of clopidogrel and diminish its antiplatelet effect.
  12. Subjects must have "good veins" for apheresis platelet collection and drawing blood samples.
  13. Women of child bearing potential must agree to use an effective method of contraception during the course of the study. The following methods of contraception will be considered 'effective' when self-reported by subject; abstinence, intrauterine contraception devices, hormonal methods, barrier methods or history of sterilization.
  14. Subject has phone and e-mail for contact and notification, and is able to come to the research site for approximately 9 visits over up to approximately 64 days.

Exclusion Criteria:

Healthy subjects will be excluded from the study for any of the following reasons:

  1. Active acute infection or suspected active infection, temperature above 100 F or taking antibiotic
  2. Active immune/inflammatory condition (e.g. gout, systemic lupus erythematosus, allograft rejection)
  3. History of heart disease, including endorsement of shortness of breath with mild exertion (at the discretion of the PI).
  4. History of significant liver, kidney, GI, blood, endocrine/metabolic, autoimmune or pulmonary disease, untreated hypertension and or metabolic syndrome (at the discretion of the PI).
  5. Diabetes Mellitus
  6. Cancer of any kind (exceptions being basal or squamous cell cancers of the skin), under treatment or resolved
  7. History of bleeding events, family history of bleeding events, or known genetic disorder with bleeding diathesis
  8. A family history of venous or arterial thrombosis before the age of 50 in first degree relatives
  9. A personal history of DVT, venous or arterial thrombosis, blood clots or stroke
  10. History of having been prescribed clopidogrel (Plavix), ticlopidine (Ticlid) or Ticagrelor (Brilinta).
  11. Subject has taken any aspirin or aspirin-containing drugs (e.g., Alka-Seltzer, Bufferin, Excedrin) or NSAIDs (e.g.,Feldene, Motrin, Aleve, Advil) or other drugs known to affect platelet function within 14 days prior to screening.
  12. Chronic NSAID therapy
  13. Chronic steroid therapy
  14. Known allergy to aspirin or clopidogrel
  15. Subjects who are taking, or have taken within 14 days any of the following class of drugs protone pump inhibitors (PPIs) such as omeprazole, pantoprazole, lansoprazole, esomeprazole lipid lowering drugs/statins anticoagulants ACE-inhibitors phenytoine tolbutamide calcium channel blockers such as amlodipine, felodipine, verapamil
  16. Current drug or alcohol dependence by subject's declaration.
  17. Currently pregnant or nursing as assessed during interview. A urine pregnancy test prior to apheresis is required for women of childbearing potential.
  18. Subject plans to participate in contact sports during study/observational period such as boxing, rugby, American football, soccer, or other risky recreational hobbies at the discretion of the investigator.
  19. Unwilling or unable to comply with the protocol in the opinion of the investigator.
  20. Participation in an experimental drug/device study within the past 30 days (other than this study). Subjects who have received an infusion on this study may not be re-enrolled.
  21. Average initial (only for the first PFT) aggregation responses to ADP less than or equal to 60% by aggregometry platelet function testing.
  22. Other unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03787927


Contacts
Layout table for location contacts
Contact: Jeffrey Miles 206-689-6285 jmiles@bloodworksnw.org

Locations
Layout table for location information
United States, Washington
Bloodworks Northwest Research Institute Recruiting
Seattle, Washington, United States, 98102
Contact: Jeffrey Miles    206-689-6285    jmiles@bloodworksnw.org   
Contact: Barbara Osborne    206-689-6346    barbarao@bloodworksnw.org   
Principal Investigator: Moritz Stolla, MD         
Sponsors and Collaborators
Bloodworks
National Blood Foundation
Investigators
Layout table for investigator information
Principal Investigator: Moritz Stolla, MD Bloodworks Northwest

Layout table for additonal information
Responsible Party: Bloodworks
ClinicalTrials.gov Identifier: NCT03787927     History of Changes
Other Study ID Numbers: 2018-02
First Posted: December 27, 2018    Key Record Dates
Last Update Posted: March 25, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Aspirin
Clopidogrel
Blood Platelet Disorders
Hematologic Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents